数据
资源
版本对比
免费注册
预约演示
免费注册
Phathom Pharmaceuticals
Announces FDA Approval of Reformulated
Vonoprazan
Tablets for
VOQUEZNA
® TRIPLE PAK®
2023-10-30
·
BioSpace
临床结果
上市批准
临床3期
引进/卖出
Planning for a December 2023 U.S. launch for H. pylori, together with the U.S. launch of
vonoprazan
for
Erosive GERD
, if approved FLORHAM PARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) --
Phathom Pharmaceuticals, Inc.
(Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for
gastrointestinal (GI) diseases
, announced that the
U.S. Food and Drug Administration (FDA)
has approved the Prior Approval Supplement (PAS) for the reformulation of
vonoprazan
tablets for both VOQUEZNA TRIPLE PAK (
vonoprazan
tablets, amoxicillin capsules,
clarithromycin
tablets) and VOQUEZNA DUAL PAK (
vonoprazan
tablets, amoxicillin capsules), for the treatment of
Helicobacter pylori (H. pylori) infection
in adults. VOQUEZNA treatment regimens contain antibiotics conveniently packaged with
vonoprazan
, a novel potassium-competitive acid blocker (PCAB) and the first innovative acid suppressant from a new drug class approved in the U.S. in over 30 years. “We are very pleased with the FDA approval of our reformulated
vonoprazan
tablets for both VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, enabling
Phathom
to market two new first-line treatment options that offer strong H. pylori eradication rates,” said Terrie Curran, President and Chief Executive Officer at
Phathom
. “H. pylori eradication failures are due to rising antibiotic resistance, inadequate acid suppression, and complex treatment regimens. We are excited about VOQUEZNA TRIPLE and DUAL PAKs, a new class of acid suppression therapy, that has the potential to address these issues and enhance H. pylori eradication. Our teams are making the final preparations for a combined December 2023 U.S. commercial launch for H. pylori along with the anticipated launch of
vonoprazan
for
Erosive GERD
, if approved. Thank you to
Phathom
employees and our manufacturing partners,
Catalent
and
Evonik
, who contributed to today’s PAS approval.” These initial product approvals were based on safety and efficacy data from the Phase 3 PHALCON-HP trial, the largest U.S. registrational trial ever conducted in H. pylori, randomizing 1,046 patients.1 In the modified intent-to-treat population, both VOQUEZNA treatment regimens demonstrated non-inferiority to
lansoprazole
triple therapy in patients without a
clarithromycin
or
amoxicillin
resistant strain of H. pylori at baseline. The H. pylori eradication rate was 84.7% with VOQUEZNA TRIPLE PAK compared to 78.8% with
lansoprazole
triple therapy [95% CI: -0.8, 12.6] and 78.5% for VOQUEZNA DUAL PAK compared to 78.8% with
lansoprazole
triple therapy [95% CI: -7.4, 6.8]. VOQUEZNA TRIPLE PAK and DUAL PAK demonstrated superior eradication rates compared to PPI-based triple therapy (
lansoprazole
with
amoxicillin
and
clarithromycin
) among all patients, including in patients with clarithromycin resistant strains of H. pylori.1 The H. pylori eradication rate with VOQUEZNA TRIPLE PAK was 80.8% versus 68.5% with
lansoprazole
triple therapy in the overall study population [95% CI: 5.7, 18.8] and in patients who had a clarithromycin-resistant strain of H. pylori, 65.8% vs. 31.9%, respectively [95% CI: 17.7, 48.1].1H. pylori eradication rates for VOQUEZNA DUAL PAK were 77.2% versus 68.5% with
lansoprazole
triple therapy in the overall study population [95% CI: 1.9, 15.4] and in patients who had a clarithromycin-resistant strain of H. pylori, 69.6% vs. 31.9%, respectively [95% CI: 20.5, 52.6].1 Adverse event (AE) rates for the
vonoprazan
-based regimens were comparable to
lansoprazole
triple therapy in the trial.1 The most common AEs (>2.0%) reported in the VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK, and
lansoprazole
triple therapy arms, respectively, were
diarrhea
(4.0%, 5.2%, 9.6%),
dysgeusia
(4.6%, 0.6%, 6.1%),
vulvovaginal candidiasis
(3.2%, 2.0%, 1.4%),
abdominal pain
(2.3%, 2.6%, 2.9%),
headache
(2.6%, 1.4%, 1.4%),
hypertension
(2.0%, 1.1%, 0.9%) and nasopharyngitis (0.3%, 2.0%, 0.9%).1 VOQUEZNA TRIPLE and DUAL PAKs are expected to be available in the U.S. in December 2023 and marketed exclusively by
Phathom Pharmaceuticals, Inc.
Phathom
is planning for a combined U.S. commercial launch of VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, together with
vonoprazan
for
Erosive GERD
, if approved.
Phathom
plans to host an investor conference call in November 2023, following FDA action on the pending
Erosive GERD
New Drug Application, which has a PDUFA target action date of November 17, to discuss the Company’s U.S. commercial launch plans. The full Prescribing Information for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK can be found here. INDICATION AND IMPORTANT SAFETY INFORMATION WhatareVOQUEZNATRIPLEPAKandVOQUEZNADUALPAK?
VOQUEZNA
® TRIPLE PAK® (
vonoprazan
tablets, amoxicillin capsules,
clarithromycin
tablets) and
VOQUEZNA
® DUAL PAK® (
vonoprazan
tablets, amoxicillin capsules) are co-packaged prescription medicines for the treatment of a
Helicobacter pylori (H. pylori) bacterial infection
in adults. It is not known if VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK are safe and effective in children. To reduce the development of drug-resistant bacteria and maintain the effectiveness of VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK and other antibacterial drugs, these products should be used only to treat or prevent
infections
that are proven or strongly suspected to be caused by susceptible bacteria. DonottakeVOQUEZNATRIPLEPAKif you are known to have an
allergy
or be sensitive to the components of VOQUEZNA TRIPLE PAK (
vonoprazan
,
amoxicillin
,
clarithromycin
),
macrolide antibiotics
(such as
azithromycin
and
erythromycin
), or
penicillin
. are taking: medicines that contain
rilpivirine
(
Edurant
,
Complera
,
Odefsey
) pimozide colchicine, if you have kidney or liver problems
lomitapide
,
lovastatin
, and
simvastatin
ergot alkaloids
(
ergotamine
or
dihydroergotamine
)
lurasidone
have a history of yellowing of the skin (
jaundice
) or liver problems when taking
clarithromycin
. DonottakeVOQUEZNADUALPAKif you are known to have an
allergy
or be sensitive to the components of VOQUEZNA DUAL PAK (
vonoprazan
,
amoxicillin
) or
penicillin
. are taking medicines that contain
rilpivirine
(Edurant, Complera, Odefsey). BeforeyoutakeVOQUEZNATRIPLEPAKorVOQUEZNADUALPAK,tellyourhealthcareprovider about all of your medical conditions, including if you are breastfeeding. If breastfeeding, pump and discard breast milk during treatment and for 2 days after treatment. have severe
kidney disease
. have moderate to severe
liver disease
. have
myasthenia gravis
. Additionally,donottakeVOQUEZNATRIPLEPAK if: you are pregnant or plan to become pregnant.
Clarithromycin
, a medicine in VOQUEZNA TRIPLE PAK may harm your unborn baby. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. There can be serious side effects when some are used in combination with this product. Serious adverse reactions can occur with VOQUEZNA TRIPLE PAK due to drug interactions of
clarithromycin
with
colchicine
, some lipid lowering agents, some calcium channel blockers, and other drugs. What are the possible side effects of VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK? VOQUEZNATRIPLEPAKorVOQUEZNADUALPAKcancauseserioussideeffectsincluding: Allergicreactions(hypersensitivity): Call your doctor right away if you have
rash
,
hives
, or other skin changes,
face swelling
or
difficulty breathing
. Atypeofkidneyproblem(acute tubulointerstitialnephritis): Some people who take VOQUEZNA may develop a kidney problem called
acute tubulointerstitial nephritis
. Call your healthcare provider right away if you have a decrease in the amount that you urinate or if you notice blood in your urine. Severeskinreactions: VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK can cause severe skin reactions, such as
skin rash
or
allergic reaction
on or in any part of your body. Symptoms can also include, but are not limited to,
fever
, chills,
body aches
or
shortness of breath
. If you experience any of these symptoms, stop taking VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK immediately and call your doctor right away. Severediarrhea: Call your doctor right away if you have
watery stool
,
stomach pain
, and
fever
that does not go away while taking VOQUEZNA DUAL PAK or VOQUEZNA TRIPLE PAK or after therapy is completed.
Rash
in patients with
mononucleosis
:
Amoxicillin
(a component of VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK) may cause a
rash
in patients who have
mononucleosis
. Stop taking VOQUEZNA TRIPLE PAK or VOQUEZNA DUAL PAK if you are diagnosed with
mononucleosis
and call your doctor right away. Altered test resultsfor some
tumors
: VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK lower stomach acid which can cause increased levels of a certain protein
(CgA)
in your blood. When this level is increased it may alter test results for detecting some
tumors
. Notify your doctor of the use of VOQUEZNA TRIPLE PAK or VOQUEZNA DUAL PAK prior to blood tests. Additionally,VOQUEZNATRIPLEPAKcancause: Irregularheartbeats:
Clarithromycin
may cause irregular heartbeats. Call your doctor right away if you feel faint, light-headed, or feel your heart beating irregularly. Liverproblems: Call your doctor right away if you have any of the following symptoms:
weight loss
, yellowing of the skin and eyes (
jaundice
), dark urine,
rash
, or
pain
on the right side of your abdomen. Themostcommonsideeffectsmayinclude:
diarrhea
temporary changes in sense of taste
vaginal yeast infection
stomach pain headache high blood pressure and cold-like symptoms These are not all of the possible side effects of VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK. Call your healthcare provider for medical advice about side effects. GeneralinformationaboutthesafeandeffectiveuseofVOQUEZNA. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use VOQUEZNA TRIPLE PAK or VOQUEZNA DUAL PAK for a condition for which it was not prescribed. Do not give VOQUEZNA TRIPLE PAK or VOQUEZNA DUAL PAK to other people, even if they have the same symptoms you have. It may harm them. For more information, ask your healthcare provider or pharmacist. YouareencouragedtoreportsuspectedadversereactionsbycontactingPhathomPharmaceuticalsat1-888- 775-PHAT (7428) or FDA at 1-800-FDA-1088 or . PleaseseefullPrescribingInformationforVOQUEZNATRIPLEPAKANDVOQUEZNADUALPAK. About
Helicobacter pylori (H. pylori) infection
H. pylori is a bacterial pathogen that is estimated to infect nearly 115 million individuals in the United States.1 If left untreated,
H. pylori infection
can lead to serious complications, such as
peptic ulcer disease
and non-cardia gastric
cancer.2
Approximately 50% of the world and 36% of the U.S. population is estimated to be infected with the bacterium. As a result of the
chronic inflammation
induced by
H. pylori infection
, infected patients may develop a range of pathologies including
dyspepsia
,
peptic ulcer disease
,
non-cardia gastric cancer
, and
mucosa-associated lymphoid tissue (MALT) lymphoma
. Studies have found that roughly 1 in 4 patients treated for H. pylori will fail first-line therapy when using PPI-based
clarithromycin
triple therapy.3 About
VOQUEZNA
® TRIPLE PAK® and
VOQUEZNA
® DUAL PAK®
VOQUEZNA
® TRIPLE PAK® (
vonoprazan
,
amoxicillin
,
clarithromycin
) and
VOQUEZNA
® DUAL PAK® (
vonoprazan
,
amoxicillin
) contain
vonoprazan
, an oral small molecule potassium-competitive acid blocker (PCAB) co-packaged with antibiotics.
PCABs
are a novel class of medicines that block acid secretion in the stomach.
Vonoprazan
has shown the potential to provide acid suppression that can achieve pH levels that are important in enhancing antibiotic effectiveness.
Phathom
in-licensed the U.S., European, and Canadian rights to
vonoprazan
from
Takeda
, which markets the product in Japan and numerous other countries in Asia and Latin America. About
Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals
is a biopharmaceutical company focused on the development and commercialization of novel treatments for
gastrointestinal diseases
.
Phathom
has in-licensed the exclusive rights in the United States, Europe, and Canada to
vonoprazan
, a first-in-class potassium-competitive acid blocker (PCAB). For more information about
Phathom
, visit the Company’s website at and follow the Company on LinkedIn and Twitter. Forward-Looking Statements This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about the timing of the commercial launch of convenience packs containing
vonoprazan
for
H. pylori infection
, the potential of
vonoprazan
-based therapies to address declining H. pylori eradication rates in the U.S., and statements regarding the PDUFA goal date and the timing of a U.S. commercial launch for
vonoprazan
for
Erosive GERD
. The inclusion of forward-looking statements should not be regarded as a representation by
Phathom
that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in
Phathom
’s business, including, without limitation: future data generated from our stability program may be different from the data submitted to the FDA to date and may not demonstrate that our mitigation efforts will continue to maintain the level of the nitrosamine impurity below the acceptable intake (AI) level throughout the shelf life of products containing
vonoprazan
, which could result in market action or shelf life reduction; risks associated with product manufacturing or formulation changes required to be made in connection with achieving the AI; the FDA may disagree that the existing safety and efficacy data, together with additional data, is sufficient to approve the Erosive GERD NDA; the inherent risks of clinical development of vonoprazan;
Phathom
’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of vonoprazan that may limit its development, regulatory approval and/or commercialization, or may result in recalls or product liability claims;
Phathom
’s ability to access additional capital under its term loan facility and royalty interest finance agreements is subject to certain conditions;
Phathom
’s ability to obtain and maintain intellectual property protection for vonoprazan;
Phathom
’s ability to comply with its license agreement with
Takeda
; and other risks described in the Company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and
Phathom
undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. MEDIA CONTACT Nick Benedetto 1-877-742-8466 media@phathompharma.com INVESTOR CONTACT Eric Sciorilli 1-877-742-8466 ir@phathompharma.com © 2023
Phathom Pharmaceuticals
. All rights reserved. VOQUEZNA, VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK,
Phathom Pharmaceuticals
, and their respective logos are registered trademarks or trademarks of
Phathom Pharmaceuticals, Inc.
10/23 US-VPZ-23-0153 1 Chey et al. ACG Clinical Guideline: Treatment of
Helicobacter pylori Infection
. Am J Gastroenterol. 2017;112:212. 2 Malfertheiner et al. Management of
Helicobacter Pylori Infection
—the Maastricht V/Florence Consensus Report. Gut. 2017;66-6. 3 Mertz et al. Helicobacter pylori Treatment & Eradication Rates in Department of Defense Patients from 2016-2018. Am J Gastroenterol. 2020;115:S664.
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Phathom Pharmaceuticals, Inc.
US Food & Drug Administration
Catalent Pharma Solutions, Inc.
[+2]
适应症
胃食管反流
胃肠道疾病
幽门螺杆菌感染
[+29]
靶点
CGA
药物
富马酸伏诺拉生
阿莫西林/富马酸伏诺拉生
克拉霉素
[+18]
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
全球潜力靶点及FIC产品研究调研报告
智慧芽生物医药
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务